MOTS-c gets talked about as an "energy peptide" and an "exercise in a vial." The real story is more interesting and more careful than that. Here is what MOTS-c is, how it works, what the research actually shows and what is still unknown.
What MOTS-c is
MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. It is a small peptide, just 16 amino acids long, and what makes it unusual is where its code lives. Almost all of the proteins in your body are written in the DNA of the cell's nucleus. MOTS-c is written in the tiny, separate genome inside the mitochondria, the structures that turn food and oxygen into usable energy.
Researchers led by Changhan Lee and Pinchas Cohen described MOTS-c in 2015, after finding a short stretch of code hidden inside a mitochondrial gene called 12S rRNA. It belongs to a small family called mitochondrial-derived peptides, which also includes humanin. These peptides suggest that mitochondria do more than make energy: they also send chemical signals to the rest of the cell and the body.
How it works: an energy signal, not an energy source
MOTS-c does not supply energy and it does not add new mitochondria. It works more like a message about the cell's energy status.
- It activates AMPK. In the original 2015 study, MOTS-c slowed a metabolic pathway called the folate cycle. That caused a natural molecule called AICAR to build up, and AICAR switches on AMPK, an enzyme that acts as the cell's fuel gauge. When AMPK is active, cells take up more glucose and burn more fat, much as they do during exercise.
- It works mainly in skeletal muscle. In mice, muscle was the main tissue where MOTS-c improved how the body handled glucose.
- It can travel to the nucleus. A 2018 study found that under stress, such as low glucose or oxidative stress, MOTS-c moves from the cytoplasm into the cell's nucleus within about 30 minutes. There it helps switch on protective genes, including antioxidant genes controlled by a factor called NRF2. That makes MOTS-c one of the clearest examples of mitochondria "talking back" to the nucleus.
- Exercise raises it. In a 2021 study, a single cycling session raised MOTS-c in the skeletal muscle of young, sedentary men nearly 12-fold, and raised blood levels by about 50%. Levels drifted back toward baseline after four hours of rest.
This is where the "mitochondria and energy" connection comes from. MOTS-c is part of how muscle senses and responds to energy demand. Whether giving extra MOTS-c from outside the body improves energy in people has not been tested.
What the research shows
Animal studies
- Metabolism: Mice given MOTS-c were protected from weight gain and insulin resistance on a high-fat diet, and treatment also prevented the insulin resistance that normally develops with age (Lee et al., 2015).
- Physical performance: In 2021, mice treated with MOTS-c ran better on treadmill and balance tests at young, middle and old ages. Treatment that started late in life improved grip strength, walking gait and performance on a walking test in the oldest mice (Reynolds et al., 2021).
These are strong, repeatable signals in mice, but mouse results often do not carry over to people.
Human studies
- Natural levels: Studies that measure the body's own MOTS-c have linked it to age, obesity and insulin resistance, but the results disagree. One study found lower blood levels in boys with obesity; another found higher MOTS-c in the muscle of older men than in younger men. These are associations, not proof of cause.
- A genetic clue: A gene variant found in some Asian populations changes one amino acid of MOTS-c. In more than 27,000 people across three cohorts, men who carried it had a higher rate of type 2 diabetes, mostly those who were physically inactive. In mice, the altered peptide lost much of its metabolic effect (Zempo et al., 2021).
- Treatment trials: No controlled trial of MOTS-c itself in people has been published. A company called CohBar tested a modified version, CB4211, in a small phase 1b study of 20 adults with obesity and fatty liver for four weeks. Liver fat fell by about the same amount in the treatment and placebo groups. Liver enzymes and blood glucose fell more with CB4211, and the most common side effect was a mild to moderate injection-site reaction. These results come from a 2021 company announcement, not a full peer-reviewed paper.
The bottom line on evidence
MOTS-c has solid early science behind it: a clear mechanism, consistent mouse data and an intriguing human genetic link. What it does not have yet is evidence from controlled human trials showing that taking it improves energy, weight, endurance or any health outcome. Anyone who tells you otherwise is getting ahead of the data.
Regulatory status
- Not FDA-approved for any use. It is sold as a research compound.
- Compounding review: In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 7 to 5, with two abstentions, to recommend adding MOTS-c to the list of bulk substances that pharmacies may compound. That vote was advisory. Read what the July 2026 vote actually means.
- Pharmacy compounding, October 2026: HHS announced that while FDA rulemaking continues, it will not take enforcement action against state-licensed (503A) pharmacies that compound MOTS-c and five other peptides for individual patients with a prescription, as long as strict conditions are met, including a pharmaceutical ingredient from an FDA-registered manufacturer with lot testing. This is an interim enforcement policy, not an FDA approval, and it excludes products sold as research chemicals.
- Sport: The World Anti-Doping Agency added MOTS-c to its Prohibited List starting in 2025, as an example of an AMPK activator. Tested athletes should treat it as banned.
Storage and handling in the lab
Like most research peptides, MOTS-c is supplied as a freeze-dried powder because it is far more stable dry than in solution. Common laboratory practice is to keep sealed vials cold, dry and out of light, and to refrigerate a reconstituted vial at 2 to 8 °C and avoid repeated freezing and thawing. Before working with any vial, match its lot number to the batch's certificate of analysis.
For the full reference page, see our MOTS-c brief. To work out concentration and syringe volumes for any vial size, use the reconstitution calculator, and see why freeze-dried peptides last longer.
Key references
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454.
- Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism. 2018;28:516-524.
- Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12.
- Zempo H, Kim SJ, Fuku N, et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging. 2021;13(2):1692-1717.
- CohBar, Inc. Topline results from the phase 1a/1b study of CB4211. Company announcement, August 10, 2021.
- Baker Hostetler. HHS issues enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, October 2026.
- U.S. Anti-Doping Agency. What's new on the 2025 WADA Prohibited List.
This post is educational. It does not give dosing guidance or recommend using any compound in people or animals.